Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Carboplatin Stories

2012-03-22 22:32:59

Scientists have uncovered a marker of DNA damage that could predict who will respond to platinum-based chemotherapy drugs like cisplatin or carboplatin. These drugs are widely used for ovarian cancer, but as with most cancer drugs, it can be difficult to predict who will respond to therapy. A team of researchers from the Dana-Farber Cancer Institute found that this marker, telomeric allelic imbalance or tAI, could predict sensitivity to therapy in patients with triple-negative breast...

2012-03-15 06:00:00

CALGARY, March 15, 2012 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the year ended December 31, 2011. "In the last year we made substantial progress as we announced positive clinical trial results and started clinical trials in additional cancer indications while maintaining the strength of our balance sheet," said Dr. Brad Thompson, President and CEO of Oncolytics....

2012-02-02 22:53:31

The internet is awash with stories of how silver can be used to treat cancer. Now, lab tests have shown that it is as effective as the leading chemotherapy drug - and may have fewer side-effects. Results from the study at the University of Leeds, published in Dalton Transactions, show that particular silver compounds are as toxic to cancer cells as the platinum-based drug Cisplatin, which is widely used to treat a range of cancers. But the crucial difference is that silver is thought to...

2011-11-14 06:00:00

CALGARY, Nov. 14, 2011 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that positive results from a Phase 2 clinical trial (REO 015) using intravenous administration of REOLYSIN(®) in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The conference is being held in San...

2011-11-07 13:27:00

SILVER SPRING, Md., Nov. 7, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Erbitux (cetuximab) for use with chemotherapy to treat patients with late-stage (metastatic) head and neck cancer. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Combined with chemotherapy, Erbitux extended the lives of those receiving the treatment combination compared with those receiving chemotherapy alone. Erbitux already is FDA-approved for certain types of...

2011-11-01 08:30:00

TSX Venture: QPT EDMONTON, Nov. 1, 2011 /PRNewswire/ - Quest PharmaTech Inc. (TSXV: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it will be making a presentation at the 2(nd) Biennial Meeting of the Asian Society of Gynecologic Oncology, in Seoul, South Korea, November 3-5. The presentation, entitled "Targeting Dendritic Cells to Create a More Powerful Immune Response: A New...

2011-10-20 07:30:00

DALLAS, October 20, 2011 /PRNewswire/ -- ReportsnReports adds multiple pharmaceutical reports on Drugs for Ovarian Cancer and Breast Cancer with their market analysis and forecasts to 2015, 2017 & 2020 (different for different drugs). A part of these research studies covers sales forecasts for US, EU, Japan and the targeted geographies, detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the...

2011-10-06 09:54:37

Treating women with early stage breast cancer with a combination of chemotherapy and the molecularly targeted drug Herceptin significantly increases survival in patients with a specific genetic mutation that results in very aggressive disease, a researcher with UCLA's Jonsson Comprehensive Cancer Center reported Wednesday. The study also found that a regimen without the drug Adriamycin, an anthracycline commonly used as a mainstay to treat breast cancer but one that, especially when paired...

2011-07-21 10:59:00

TSX Venture: QPT EDMONTON, July 21, 2011 /PRNewswire/ - Quest PharmaTech Inc. (TSXV: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has received notice of allowance for U.S. Patent Application 10/831,886 entitled: "Combination Therapy for Treating Disease" (the "Patent"). The Patent covers the use of monoclonal antibodies capable of targeting tumor antigens CA 125, MUC1, CA 19.9,...

2011-07-06 06:00:00

CALGARY, July 6, 2011 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics") today announced that a presentation covering interim preliminary results from a Phase 2 clinical trial using intravenous administration of REOLYSIN(® )in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumours was made today at the International Association for the Study of Lung Cancer World...